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In this issue of Cell, the Calmodulin binding transcription activator 2 (CAMTA2), is shown by 
Song et al. (2006) to be an indispensable transcription coactivator for cardiac hypertrophy. 
CAMTA2 is activated by the dissociation of class II histone deacetylase 5 and promotes 
transcription of genes involved in cardiac hypertrophy through its interaction with Nkx2-5.For adult cardiac muscle—the sin-
gle most common target of disease 
in the elderly—the characteristic 
response to injury is myocyte hyper-
trophy (Olson and Schneider, 2003). 
However, myocyte hypertrophy is 
much more than a global growth 
response and includes other stereo-
typic features such as intrinsic myo-
cyte dysfunction that is due in part to 
transcriptional reprogramming. This 
reprogramming leads to the reactiva-
tion of cardiac-specific genes asso-
ciated with the fetal myocardium and 
the downregulation of several essen-
tial genes whose normal expression 
is highest in adult hearts. Depending 
on the severity, duration, and type of 
instigating signal, a second hallmark 
of hypertrophy can be progression to 
a “heart failure” phenotype, with ven-
tricular wall thinning, chamber dila-
tion, and, typically, ongoing myocyte 
death through apoptosis. In short, in 
heart disease, the myocytes are both 
depressed and suicidal.
Over the past two decades, a prin-
cipal objective in cardiac biology has 
been to comprehend in molecular 
detail how pathological signals such 
as high blood pressure, or the signals 
that compensate for the ischemic 
loss of myocytes in heart attacks, 
lead to and orchestrate the observed 
ensemble of genomic responses. 
Many signaling modules have been 
implicated as sufficient or, more 
rarely, as necessary for hypertrophy. 
Many of these, in turn, share three 
properties. The first is extensive 
crosstalk and interconnection, pos-
ing challenges that are common to studies of signal transduction in any 
context. The second, more uniquely, 
is that many hypertrophic signaling 
cascades ultimately engage the cel-
lular circuits that control growth and 
gene expression in the embryonic 
heart. A third, established in large 
part by Eric Olson and colleagues, 
is the role of intracellular calcium, 
involving the calcium binding pro-
tein calmodulin, calcium-dependent 
export of particular corepressors 
(such as class II histone deacety-
lases), and other calcium-dependent 
events that have eluded definition.
In this issue of Cell, Olson and 
colleagues report their discovery 
of a new regulator of cardiac gene 
expression and growth (Song et al., 
2006). Using a eukaryotic expres-
sion screen for cDNAs that activate 
the atrial natriuretic factor (ANF) 
promoter, a cardiac-specific marker 
of hypertrophy and pathological 
remodeling, the authors hit upon 
a potent inducer, called calmodu-
lin binding transcription activator 2 
(CAMTA2), one of a family of previ-
ously described but little-studied 
proteins that are conserved from 
plants to humans. They were first dis-
covered in plants as stress-respon-
sive regulators of gene transcription 
that respond to calcium/calmodulin 
(Yang and Poovaiah, 2002; Bouche 
et al., 2002). The existence of two 
CAMTA genes was known for mice 
and humans, but their functions 
were utterly unknown. Both are most 
highly expressed in heart and brain, 
with relative expression in heart high-
est for CAMTA2.Cell 12Interestingly, the physical recruit-
ment of CAMTAs to the ANF pro-
moter occurred indirectly, at least 
in part, through association with an 
essential cardiac homeodomain pro-
tein, Nkx2-5, and CAMTA2 hence 
acted as a coactivator for Nkx2-5. 
The Nkx2-5 binding site in the ANF 
promoter was required for maximal 
activation by CAMTA2. A single copy 
of the Nkx2-5 binding site was suf-
ficient to confer CAMTA responsive-
ness to a basal promoter, and muta-
tions blocking the protein-protein 
interaction abolished the ability of 
CAMTA2 to support Nkx2-5-depend-
ent ANF induction.
Nkx2-5 is the mouse ortholog 
of Tinman, a homeobox gene that 
is obligatory for the formation of 
the rudimentary heart tube in flies. 
Although it is dispensable in mice 
for cardiac myogenesis, perhaps 
because of family members with 
overlapping expression, Nkx2-5 is 
nevertheless essential in mice for 
normal cardiac morphogenesis to 
transpire, and mutations in Nkx2-5 
cause a spectrum of cardiac abnor-
malities in humans (reviewed in Prall 
et al., 2002). However, evidence 
implicating Nkx2-5 in the control 
of cardiac growth is problematic in 
a developmental context because 
altered cardiac muscle mass might 
reflect altered cell fate decisions or 
be a secondary response to dys-
morphogenesis and the resultant 
abnormal hemodynamics. Hence, it 
is intriguing that Olson’s study sug-
gests that the induction of cardiac 
hypertrophy by CAMTA2 was medi-5, May 5, 2006 ©2006 Elsevier Inc. 427
Figure 1. CAMTA2 in Hypertrophic 
 Signaling in the Heart
(Left panel) Based on Song et al. (2006), 
CAMTA2 is repressed by an association 
with class II histone deacetylases (HDACs). 
(Right panel) Activation of protein kinase D 
(PKD) signaling leads to phosphorylation of 
class II HDACs, which create docking sites 
for 14-3-3 proteins and their nuclear export, 
thus releasing CAMTA2 from repression 
and promoting cardiac growth. The interac-
tion between the CG-1 domain of CAMTA2 
and the homeodomain of Nkx2-5 activates 
downstream cardiac hypertophic gene tar-
gets via binding to the Nkx2-5-response 
element (NKE). CAMTA2 domains defined 
by mutagenesis and functional analysis are 
as follows: CG-1 is involved in Nkx2-5 bind-
ing and nuclear export, TAD is required for 
transcriptional activation, TIG stabilizes the 
interaction with Nkx2-5, ANK is an ankyrin 
repression domain that binds HDAC5, and 
the nuclear localization signal (NLS) func-
tions in nuclear import.ated, at least in part, through its 
association with Nkx2-5. The asso-
ciation of transcription factors with 
coactivators (and corepressors) 
allows for signal-dependent regula-
tion of gene expression and expands 
the regulatory potential of cis-acting 
DNA sequences as a consequence 
of combinatorial protein-protein 
interactions. The present findings 
do not exclude other possibilities, 
including the potential for CAMTA 
to bind the DNA sequence, CGCG 
(Yang and Poovaiah, 2002), which 
might stabilize its interactions with 
Nkx2-5 and other cofactors. Nota-
bly, because Nkx2-5 associates 
with many cardiogenic transcription 
factors, including SRF, GATA4, and 
Tbx5 (Chen and Schwartz, 1996; 
Durocher et al., 1997; Hiroi et al., 
2001), it will be important to deter-
mine if CAMTA can activate Nkx2-
5-dependent transcription in those 
contrasting settings where Nkx2-5 is 
tethered to DNA indirectly via these 
other factors. In addition, as CAMTA 
and many other factors physically 
interact with the homeodomain of 
Nkx2-5, it will be intriguing to learn 
which interactions can coexist and 
which, if any, are mutually exclusive. 
CAMTA2 did not show appreciable 
expression in the heart until after 
birth, whereas CAMTA1 was strongly 
expressed in the embryonic heart 
(Song et al., 2006); given their high 
degree of sequence conservation, it 428 Cell 125, May 5, 2006 ©2006 Elsevieis surmised (but not yet proven) that 
CAMTA1 will modulate the develop-
mental functions of Nkx2-5.
Multiple functional domains were 
found in CAMTA2 that are evolu-
tionarily conserved (Figure 1). These 
include the CG-1 domain (required for 
association of CAMTA2 with Nkx2-5 
and activation of Nkx2-5-depend-
ent promoters), the TIG domain 
(which may stabilize the interaction 
with Nkx2-5), the IQ motifs (which 
bind calmodulin, in the case of plant 
CAMTA proteins, yet are dispensa-
ble for trans-activation here; Bouche 
et al., 2002; Yang and Poovaiah, 
2002), and an ankyrin repeat. The 
ankyrin repeat of CAMTA2 associ-
ates with class II HDACs and nega-
tively modulates the function of the 
trans-activation domain, much as 
in other ankyrin-repeat-containing 
transcriptional activators (McKinsey 
et al., 2006).
Through gain- and loss-of-func-
tion approaches in vivo and in vitro, 
Olson and colleagues show persua-
sively that class II HDACs restrain 
trans-activation by CAMTA proteins. 
Nuclear export of class II HDACs 
in response to signaling by protein 
kinase C (PKC) and PKD releases 
CAMTAs from HDAC-dependent 
repression and consequently induces 
the genes for cardiac hypertrophy. 
By constrast, a mutant of HDAC that 
is “signal resistant” because it lacks 
the phosphorylation sites for nuclear r Inc.export blocks CAMTA activity even 
in the face of PKC signaling. Elevat-
ing CAMTA2 expression by adeno-
viral gene transfer caused cardio-
myocytes in culture to become both 
larger and more numerous. Elevating 
CAMTA2 in transgenic mice, using 
the heart-specific α-myosin heavy 
chain (MHC) promoter, caused car-
diac hypertrophy as assessed by wall 
thickness, cell size, and molecular 
markers, and all transgenic animals 
died by 12 weeks of age, with dilated 
cardiomyopathy and heart failure. 
Despite equal or greater expression 
of the transgene-encoded protein, 
mice expressing the ∆206 CAMTA2 
mutant, which cannot associate with 
Nkx2-5, did not develop hypertrophy. 
Conversely, hypertrophy induced by 
expression of CAMTA2 by the αMHC 
promoter was potentiated in mice 
lacking HDAC5, whereas mice lack-
ing CAMTA2 showed diminished 
hypertrophy in response to con-
striction of the aorta (which causes 
increased workload) and the infusion 
of the hypertropic agonists, angi-
otensin II or isoproterenol.
Thus, CAMTA2 was found to be 
an essential signal-responsive tran-
scriptional coactivator for cardiac 
hypertrophy that becomes activated 
by the dissociation of class II HDACs. 
Based on the authors’ prior work on 
calcium-dependent export of HDACs 
from the nucleus, it is implied, quite 
convincingly, that CAMTA proteins 
likely function in the pathway for 
“excitation-transcription coupling” 
in the heart. Inositol 1,4,5-trisphos-
phate receptors in the nuclear enve-
lope mediate spatially restricted cal-
cium release, which is instrumental 
to this process (Wu et al., 2006).
The present report in Cell poses 
as many exciting questions as it 
answers—a very fair and rewarding 
trade. How does CAMTA2 engage a 
growth program—is Nkx2-5 or some 
other DNA bound factor the critical 
intermediate for growth? Given the 
many growth factors that are induced 
or activated in hypertrophic cells, 
are the trophic effects of CAMTA 
exclusively cell autonomous? Does 
CAMTA2 participate in those aspects 
of hypertrophy that were not yet stud-
ied (the predisposition to cell death, 
the dysregulation of nuclear genes 
for mitochondrial proteins, the loss Tissue development proceeds 
within the context of an organized 
extracellular matrix (ECM) micro-
environment and is temporally con-
trolled by transcriptional programs 
initiated by soluble and insoluble 
cues. Tissues are three dimen-
sional (3D) and exert—and are sub-
ject to—forces that profoundly alter 
their behavior. Dynamic extrinsic 
and intrinsic forces modify cell fate 
by influencing membrane-receptor 
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One goal of biomedical resear
therapy and to promote tissue
insight into the molecular bas
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utes to the three-dimensional of αMHC and calcium-handling pro-
teins) or in those modes of hypertro-
phy referred to as more “physiologi-
cal” because they are triggered by 
exercise or the IGF-PI3K-Akt path-
way? Even if CAMTA2 and CAMTA1 
are functionally indistinguishable as 
ascertained in vitro, the differential 
expression of CAMTA1 (in the early 
stages of heart development) versus 
CAMTA2 (at later ages) prompts the 
speculation that CAMTA1 might have 
the more obvious place in both car-
diac development and in human con-
genital heart disease.
ReFeRenCeS
Bouche, N., Scharlat, A., Snedden, W., Bou-
chez, D., and Fromm, H. (2002). J. Biol. Chem. 
277, 21851–21861.
Chen, C.Y., and Schwartz, R.J. (1996). Mol. 
Cell. Biol. 16, 6372–6384.Cell 12
and ion-channel activity, by alter-
ing cytoskeletal organization and 
nuclear shape, and by modulat-
ing tissue organization and gene 
expression (for review, see Orr et 
al., 2006). As development pro-
ceeds, increasingly elaborate and 
specialized 3D tissue structures 
are assembled, with the cytoarchi-
tecture and tissue-specific forces 
in each organ reflecting the spe-
cialized function of the tissue (for 
ird Dimension
2,*
t of Surgery, University of California, San Fra
partment of Pathology, University of Pennsy
ch is to reliably construct surro
 regeneration. In this issue of C
is of tissue-specific differentia
r matrix by the matrix metallop
development of white adipose Durocher, D., Charron, F., Warren, R., 
Schwartz, R.J., and Nemer, M. (1997). EMBO 
J. 15, 5687–5696.
Hiroi, Y., Kudoh, S., Monzen, K., Ikeda, Y., 
Yazaki, Y., Nagai, R., and Komuro, I. (2001). 
Nat. Genet. 28, 276–280.
McKinsey, T.A., Kuwahara, K., Bezprozvan-
naya, S., and Olson, E.N. (2006). Mol. Biol. 
Cell 17, 438–447.
Olson, E.N., and Schneider, M.D. (2003). 
Genes Dev. 17, 1937–1956.
Prall, O.W., Elliott, D.A., and Harvey, R.P. 
(2002). Ann. Med. 34, 148–156.
Song, K., Backs, J., McAnally, J., Qi, X., Ge-
rard, R.D., Richardson, J.A., Hill, J.A., Bas-
sell-Duby, R., and Olson, E.N. (2006). Cell, 
this issue.
Wu, X., Zhang, T., Bossuyt, J., Li, X., McKin-
sey, T.A., Dedman, J.R., Olson, E.N., Chen, J., 
Brown, J.H., and Bers, D.M. (2006). J. Clin. 
Invest. 116, 675–682.
Yang, T., and Poovaiah, B.W. (2002). J. Biol. 
Chem. 277, 45049–45058.5, May 5, 2006 ©2006 Elsevier Inc. 429
review, see Nelson et al., 2005). As 
each specialized tissue develops, 
it produces a unique biochemical 
and organizational ECM in which 
it becomes enmeshed. The ECM 
in turn influences the ability of 
the tissue to sense the magnitude 
and duration of extrinsic forces. 
This force then impacts signaling 
cascades that direct expression 
of genes important for differentia-
tion. Accordingly, the biochemical 
ncisco, San Francisco, CA 94143, USA
lvania, Philadelphia, PA 19104, USA
gate tissues for replacement 
ell, Chun et al. (2006) provide 
tion. The authors show that 
roteinase MT1-MMP contrib-
tissue in mice.
